British Journal of Haematology最新文献

{"title":"Fibrinogen genotypes and their impact on recurrence of venous thromboembolism and family history: A prospective population-based study","authors":"Ashfaque A. Memon,&nbsp;Bengt Zöller,&nbsp;Peter J. Svensson,&nbsp;Jan Sundquist,&nbsp;Kristina Sundquist","doi":"10.1111/bjh.19999","DOIUrl":"10.1111/bjh.19999","url":null,"abstract":"<p>Venous thromboembolism (VTE) involves blood clot formation in veins, resulting in serious health issues. Fibrinogen, a crucial clotting protein, consists of three polypeptides encoded by the fibrinogen genes: alpha (<i>FGA</i>), beta (<i>FGB</i>) and gamma (<i>FGG</i>). We genotyped most common missense variants in the fibrinogen genes in relation to VTE, recurrence and family history in Malmö Thrombophilia Study, including 1465 VTE patients followed for ~10 years and 429 healthy donors. <i>FGG</i> (rs6063) was significantly associated with increased odds of primary VTE (odds ratio [OR] = 8.2; 95% confidence interval [CI] = 1.05–63.6) after adjusting for age and sex. For recurrent VTE, Cox-regression analysis indicated a higher risk associated with <i>FGA</i> (rs6050) (hazard ratio [HR] = 1.8; 95% CI = 1.1–2.8), with even greater risk for unprovoked recurrent VTE (HR = 2.3; 95% CI = 1.3–4.2), surpassing the well-known factor V Leiden (FVL) (HR = 1.9; 95% CI = 1.2–3.0). Combining risk alleles from FVL and <i>FGA</i> (rs6050) significantly raised the risk for unprovoked recurrent VTE: ≥3 risk alleles (HR = 4.6; 95% CI = 1.9–11.3), two risk alleles (HR = 2.6; 95% CI = 1.4–4.8) and one risk allele (HR = 1.5; 95% CI = 0.8–2.7) compared to 0 risk allele. Prevalence of <i>FGA</i> (rs6050) risk allele was significantly higher in cases with a family history of VTE. We propose <i>FGA</i> (rs6050) as a novel predictor for unprovoked recurrent VTE and it may contribute to the familial occurrence of VTE.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"206 2","pages":"657-665"},"PeriodicalIF":5.1,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19999","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142996835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAR T access and outcomes in large B-cell lymphoma according to ethnicity and socioeconomic deprivation in the UK.","authors":"Diana Dragoi, Samuel Cusworth, Laura Oldham, Robin Sanderson, Jane Norman, Joht Chandan, Amrith Mathew, Emil Kumar, Shankara Paneesha, Eleni Tholouli, Andres Moya Davila, Styliani Bouziana, Piers Patten, Prudence Hardefeldt, Deborah Yallop, Sridhar Chaganti, David Burns, Andrea Kuhnl","doi":"10.1111/bjh.19997","DOIUrl":"https://doi.org/10.1111/bjh.19997","url":null,"abstract":"<p><p>Data on the impact of ethnic and socioeconomic factors on Chimeric antigen receptor (CAR) T-cell therapy (access and outcomes are limited, but key to understand whether results from the registration trials are generalizable to real-world patient populations. Here, we analysed ethnicity, socioeconomic deprivation and referral patterns in a cohort of 314 large B-cell lymphoma patients approved for third-line CD19 CAR-T across three large UK CAR-T centres. Patients from deprived areas had a lower infusion rate compared to low deprivation areas (73% vs. 86%, p = 0.04). CAR-T response rates, toxicities, progression-free survival or non-relapse mortality were similar with respect to ethnicity or deprivation. We did not find evidence of referral barriers according to ethnicity, but potential regional barriers for socioeconomically deprived patients in two of three centres. Intention-to-treat overall survival was significantly inferior in patients from deprived areas (1-year OS 44.5% vs. 58% for high vs. low deprivation; p = 0.02), likely reflecting general health disparities and higher drop-out rates in this group. Our data suggest similar outcomes of CD19 CAR-T-treated patients across a socioeconomically and ethnically heterogeneous real-world population. Results demonstrate broad access to CAR-T within the UK national delivery system, but the high drop-out rate and potential regional referral barriers for deprived communities should be further investigated.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142996832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JAK2 is a critical therapeutic target in VEXAS syndrome treated with ruxolitinib","authors":"Andrea Ceccardi,&nbsp;Martina Dameri,&nbsp;Francesco Ravera,&nbsp;Nicolò Gilardi,&nbsp;Mario Stabile,&nbsp;Isabella Lombardo,&nbsp;Davide Ceresa,&nbsp;Monica Colombo,&nbsp;Tiziana Vigo,&nbsp;Benedetta Cigolini,&nbsp;Giulia Rivoli,&nbsp;Matteo Dragani,&nbsp;Irene Solimano,&nbsp;Anna Garuti,&nbsp;Andrea Bellodi,&nbsp;Alberto Ballestrero,&nbsp;Lorenzo Ferrando,&nbsp;Gabriele Zoppoli","doi":"10.1111/bjh.19979","DOIUrl":"10.1111/bjh.19979","url":null,"abstract":"&lt;p&gt;Vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic (VEXAS) syndrome, first identified by Beck et al.,&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; is an acquired monogenic autoinflammatory disorder characterized by multisystemic relapsing inflammation, often accompanied by multilineage cytopenia, venous thromboembolism, myelodysplastic syndrome and monoclonal gammopathy. VEXAS is caused by post-zygotic mutations of the ubiquitin-like modifier activating enzyme 1 (&lt;i&gt;UBA1&lt;/i&gt;) gene within haematopoietic stem cells, resulting in the disruption of the ubiquitin–proteasome pathway.&lt;span&gt;&lt;sup&gt;1, 2&lt;/sup&gt;&lt;/span&gt; Recent research indicates that these aberrations ultimately cause abnormal myeloid cell cycling and increased cytokine production by monocytes.&lt;span&gt;&lt;sup&gt;3, 4&lt;/sup&gt;&lt;/span&gt; Nevertheless, the pathophysiology of VEXAS remains only partially understood, preventing the identification of actionable therapeutic targets.&lt;/p&gt;&lt;p&gt;Consistently with these knowledge gaps, few therapeutic options are currently available for the management of VEXAS. Indeed, while high-dose steroids are beneficial during disease flares, their long-term utilization is discouraged by their side effects. On the other hand, conventional disease-modifying anti-rheumatic drugs are scarcely useful for the management of inflammatory symptoms.&lt;span&gt;&lt;sup&gt;2, 5, 6&lt;/sup&gt;&lt;/span&gt; Recent retrospective studies have identified Janus kinase inhibitors (JAKi) as effective therapeutic agents for patients with VEXAS.&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; Of these, ruxolitinib, a dual inhibitor of JAK1 and JAK2, is associated with higher response rates compared to other JAKi.&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; However, the mechanisms by which patients with VEXAS respond more to ruxolitinib than other JAKi are still unclear. Addressing this knowledge gap is critical for discovering the specific actionable targets in VEXAS, possibly allowing for the optimization of current therapeutic strategies.&lt;/p&gt;&lt;p&gt;To dissect the molecular characteristics of response to dual JAK inhibition, we charted the transcriptomic response to therapy in one patient with VEXAS treated with ruxolitinib. The patient, a 63-year-old Caucasian man, was diagnosed with VEXAS by genetic testing in April 2023 following an extensive diagnostic work-up for unexplained inflammatory symptoms, empirically treated with corticosteroids. VEXAS coexisted with WHO-defined myelodysplastic syndrome with low blasts&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; and immunoglobulin M monoclonal gammopathy of undetermined significance (MGUS). Azacytidine was initiated in mid-May 2023, with contemporary steroid tapering. By early June, the patient required hospitalization due to high remittent fever, diffuse purpuric rash and enanthem. The biopsy of a purpuric skin lesion revealed dermic neutrophil and lympho-monocytic infiltrates positive for myeloperoxidase, confirming the diagnosis of VEXAS flare. Following initial treatment with intravenous steroids, ruxolitinib was initiated as steroid-sparing agent,","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"206 2","pages":"758-762"},"PeriodicalIF":5.1,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19979","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142996838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic melanoma presenting with leucoerythroblastic blood film","authors":"Carlo Zaninetti,&nbsp;Maria Einweg,&nbsp;Alexandra Almann,&nbsp;Adrian Schwarzer","doi":"10.1111/bjh.19974","DOIUrl":"10.1111/bjh.19974","url":null,"abstract":"<p>A 58-year-old male patient presented with abdominal pain, fever and cutaneous bleeding. Routine laboratory tests showed anaemia (haemoglobin concentration: 91.8 g/L), thrombocytopenia (platelet count: 24 × 10⁹/L), haemolysis (haptoglobin: &lt;10 g/L, lactate dehydrogenase: 7380 U/L), evidence of fibrinolysis (D-dimer: 4.1 mg/L, fibrinogen: 0.9 g/L) and acute kidney injury (glomerular filtration rate: 29 mL/min). A suspicion of thrombotic microangiopathy (PLASMIC score 5, intermediate risk) was promptly raised, and a peripheral blood film was performed to search for schistocytes. The blood film showed no evidence of schistocytes, but revealed a leucoerythroblastic reaction with reticulocytes, polychromatic erythroblasts (May–Grünwald–Giemsa staining, 60× objective; bottom left main panel) and coexistence of mature and immature granulocytes (top left). Reticulocytes were also readily detectable by immunofluorescence microscopy with immunostaining of the cytoskeletal protein non-muscular myosin IIa showing typical aggregates (bottom left, inset). A review of patient's medical history revealed a previous diagnosis of malignant melanoma treated with surgery 2 years earlier, with subsequent development of axillary lymph node and lung metastases during treatment with checkpoint inhibitor therapy. At presentation, the patient was receiving a combination chemotherapy with dabrafenib and trametinib targeting the <i>BRAF</i> and <i>MEK</i> genes. Bone marrow metastasis from melanoma was suspected, and a bone marrow aspiration and biopsy were performed. The aspiration revealed a diffuse infiltration of the bone marrow with large, vacuolated cells with large, open-chromatin nuclei and prominent nucleoli (May–Grünwald–Giemsa staining, 60× objective; right main panel). A small proportion of these cells displayed melanin pigment (upper right, inset). The cells were CD45-negative by flow cytometry, confirming their non-haematopoietic origin. A computed tomography scan revealed multiple hepatic metastases. The patient was treated palliative and died few days later.</p><p>The reported case reaffirms the importance of peripheral blood morphology, which can uniquely guide the diagnostic workup even in the era of precision medicine.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"206 3","pages":"814"},"PeriodicalIF":5.1,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19974","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypomethylating agents for patients with VEXAS without myelodysplastic syndrome: Clinical outcome and longitudinal follow-up of vacuolization and UBA1 clonal dynamics","authors":"Jose R. Álamo,&nbsp;Lucía Mont-de Torres,&nbsp;Sandra Castaño-Díez,&nbsp;Anna Mensa-Vilaró,&nbsp;M. Mónica López-Guerra,&nbsp;Ines Zugasti,&nbsp;Johana Díaz,&nbsp;Carlos Jiménez-Vicente,&nbsp;Susana Plaza,&nbsp;Virginia Fabregat,&nbsp;Iñaki Ortiz de Landazuri,&nbsp;Jordi Yagüe,&nbsp;Gerard Espinosa,&nbsp;Raimon Sanmartí,&nbsp;Maria Rozman,&nbsp;Francesca Guijarro,&nbsp;Albert Cortes,&nbsp;Ana Triguero,&nbsp;Aina Cardús,&nbsp;Adriana Cuartas,&nbsp;Marina Cornejo,&nbsp;Jordi Esteve,&nbsp;Juan I. Aróstegui,&nbsp;Marina Díaz-Beyá","doi":"10.1111/bjh.19953","DOIUrl":"10.1111/bjh.19953","url":null,"abstract":"<div>\u0000 \u0000 <p>VEXAS syndrome is a haemato-inflammatory disease caused by somatic <i>UBA1</i> mutations and characterized by cytoplasmic vacuoles in myeloid and erythroid precursor cells. Although there is currently no standard treatment algorithm for VEXAS, patients are generally treated with anti-inflammatory therapies focused on symptom management, with only partial effectiveness. Hypomethylating agents (HMA) have shown promise in VEXAS patients with concomitant myelodysplastic syndrome (MDS), while the efficacy of HMA in VEXAS patients without MDS is largely unknown. Furthermore, the usefulness of monitoring the variant allele frequency (VAF) of <i>UBA1</i> or vacuolization in precursor cells over the course of treatment has not been extensively investigated. We have evaluated the efficacy of HMA in four VEXAS patients without MDS and performed longitudinal analyses of the VAF of <i>UBA1</i> and vacuolization during treatment. HMA treatment led to overall clinical improvement, a dramatic reduction in the VAF of <i>UBA1</i>, normalization of haematological and inflammatory markers and a quantifiable decrease in vacuolization, leading us to speculate that unlike anti-inflammatory therapies, HMA may well act as a disease-modifying treatment. If these findings are confirmed in further studies, it could lead to the early use of HMA in the treatment of all VEXAS patients—with or without MDS.</p>\u0000 </div>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"206 2","pages":"565-575"},"PeriodicalIF":5.1,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142976875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paediatric anaplastic large-cell lymphoma with cardiac tamponade.","authors":"Takahiro Shiwaku, Kosuke Tamefusa, Hisashi Ishida, Kaori Fujiwara, Kana Washio, Hirokazu Tsukahara","doi":"10.1111/bjh.19980","DOIUrl":"https://doi.org/10.1111/bjh.19980","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eosinophils gone missing: The analyser mix-up mystery","authors":"Radu Chiriac,&nbsp;Fanélie Mestrallet,&nbsp;Cécile Dumas,&nbsp;Sandrine Girard,&nbsp;Marie-Virginie Larcher,&nbsp;Laurent Jallades","doi":"10.1111/bjh.19977","DOIUrl":"10.1111/bjh.19977","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"206 3","pages":"815-816"},"PeriodicalIF":5.1,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The higher initial dose and accelerated titration regimen of ropeginterferon as a treatment option for certain patients with polycythaemia vera","authors":"Albert Qin,&nbsp;Lei Zhang,&nbsp;Jie Jin","doi":"10.1111/bjh.19998","DOIUrl":"10.1111/bjh.19998","url":null,"abstract":"&lt;p&gt;We agree with the insights and comments in the Letter to the Editor by Drs. Barbui, Tefferi and Vannucchi in response to our report of the 2-year results with ropeginterferon alpha-2b (ropeg) for the treatment of polycythaemia vera (PV) by using a higher initial dose and accelerated titration (HIDAT) regimen.&lt;span&gt;&lt;sup&gt;1, 2&lt;/sup&gt;&lt;/span&gt; We believe that the HIDAT regimen of ropeg represents an appropriate treatment option for certain patients with PV based on clinical and haematological parameters, and &lt;i&gt;Janus kinase 2&lt;/i&gt; (&lt;i&gt;JAK2&lt;/i&gt;) mutant allele burden.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Using the standard approved dosing regimen of ropeg in the management of PV, the PROUD-PV/CONTINUATION-PV study has demonstrated the durable complete haematological response (CHR), reduction of &lt;i&gt;JAK2&lt;/i&gt;V617F allele burden and long-term clinical benefits including event-free survival attainable with ropeg.&lt;span&gt;&lt;sup&gt;4, 5&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;While ethnic sensitivity analyses have shown that ropeg is effective across diverse patient populations,&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; the management of PV should be individualized according to disease and patient characteristics as well as desired treatment outcomes. PV is a neoplasm with heterogeneous clinical manifestations and disease course.&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; Patients present with a wide range of clinical signs and symptoms including different degrees of splenomegaly.&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt; The clinical course for neoplastic transformation to myelofibrosis (MF) or acute myeloid leukaemia (AML), and haematological disease progression as defined by Barbui et al.,&lt;span&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/span&gt; also differs among patients. Evidence-based alternative dosing options allow physicians to make informed decisions in the flexibility to individualize ropeg dose and schedule. While PV is almost universally associated with a &lt;i&gt;JAK2&lt;/i&gt; mutation, a &lt;i&gt;JAK2&lt;/i&gt; mutation alone does not appear to be sufficient to confer the PV phenotype. Rather, the occurrence and progression of PV results from clonal expansion of cells harbouring a driver &lt;i&gt;JAK2&lt;/i&gt; mutation, coexisting or passenger mutations and perhaps epigenetic changes. Therefore, a logical treatment approach is one that suppresses neoplastic cell-intrinsic growth regulatory signals, and not just the &lt;i&gt;JAK2&lt;/i&gt; kinase alone.&lt;span&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/span&gt; Ropeg is an interferon (IFN)-based therapy which could activate a network of tumour suppressor and cell cycle regulatory proteins.&lt;span&gt;&lt;sup&gt;10-12&lt;/sup&gt;&lt;/span&gt; Given its anti-clonal activities directly on neoplastic cells and immunomodulatory effect on the immune system, ropeg has the potential to eradicate the neoplastic clones associated with PV.&lt;/p&gt;&lt;p&gt;&lt;i&gt;JAK2&lt;/i&gt;V617F allele burden or variant allele frequency (VAF) in peripheral blood is a reliable marker of disease burden, and treatment effect associated with in vivo exposure to ropeg.&lt;span&gt;&lt;sup&gt;10, 13&lt;/sup&gt;&lt;/span&gt; Available data suggest that elevated &lt;i&gt;JAK2&lt;/i&gt;V617F VAF is associat","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"206 3","pages":"986-987"},"PeriodicalIF":5.1,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.19998","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concomitant HIV-associated plasmablastic lymphoma and visceral leishmaniasis at initial presentation","authors":"Radu Chiriac","doi":"10.1111/bjh.19971","DOIUrl":"10.1111/bjh.19971","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"206 2","pages":"414-415"},"PeriodicalIF":5.1,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The dosage of ropeginterferon in polycythaemia vera: Balancing efficacy, safety and pharmacoeconomics across risk categories","authors":"Tiziano Barbui,&nbsp;Ayalew Tefferi,&nbsp;Alessandro M. Vannucchi","doi":"10.1111/bjh.19996","DOIUrl":"10.1111/bjh.19996","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"206 3","pages":"984-985"},"PeriodicalIF":5.1,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}